

LEGAL REPRESENTATIVE: Kirton & McConkie, Krieger, Michael F.
NUMBER OF CLAIMS: 37
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT: 919
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s 114 and migraine/ab
L15 0 L14 AND MIGRAINE/AB

=> s 114 and migraine
L16 3 L14 AND MIGRAINE

=> s 114 and migraine/ab
L17 60 L14 AND MIGRAINE/AB

=> d ibib abs 60

L17 ANSWER 60 OF 60 USPAT2 on STN
ACCESSION NUMBER: 2002:27500 USPAT2 Full-text
TITLE: Method of treating migraines and pharmaceutical compositions
INVENTOR(S): Smitchieva, Kremena, Basking Ridge, NJ, United States
Reines, Scott A., New Hope, PA, United States
McKinney, Errol, Doylestown, PA, United States
Sandquest, Eric J., Doylestown, PA, United States
Khanuma, Deepak K., Furlong, PA, United States
Hargreaves, Richard, Terlings Park, UNITED KINGDOM
Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

PATENT ASSIGNEE(S):

NUMBER KIND DATE

PATENT INFORMATION: US 6384034 B2 20020507
APPLICATION INFO.: US 2001-934823 20010822 (9)
RELATED APPLN. INFO.: Continuation of Ser. No. US 1999-429274, filed on 29 Oct 1999, now abandoned

NUMBER DATE

PRIORITY INFORMATION: US 1998-106605P 19981102 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Jarvis, William R. A.
ASSISTANT EXAMINER: Kim, Vickie
LEGAL REPRESENTATIVE: Yuro, Raymond, Billups, Richard C., Rose, David L.
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 345
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A combination of a 5HT.sub.1B/1D agonist and a COX-2 selective inhibitor is useful in the treatment and of prevention of migraine.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d ibib abs 59

L17 ANSWER 59 OF 60 USPAT2 on STN
ACCESSION NUMBER: 2006:175340 USPAT2 Full-text
TITLE: Benzodiazepine CGRP receptor antagonists
INVENTOR(S): Burgey, Christopher S., Philadelphia, PA, UNITED STATES
Stump, Craig A., Pottstown, PA, UNITED STATES
Williams, Theresa M., Harleysville, NJ, UNITED STATES

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTARHH1626

PASSWORD:

***** RECONNECTED TO STN INTERNATIONAL *****
SESSION RESUMED IN FILE 'USPATFULL, USPAT2' AT 13:08:14 ON 04 APR 2007
FILE 'USPATFULL' ENTERED AT 13:08:14 ON 04 APR 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
FILE 'USPAT2' ENTERED AT 13:08:14 ON 04 APR 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS SINCE FILE TOTAL
FULL ESTIMATED COST ENTRY SESSION
130.00 187.55

=> file uspatall
COST IN U.S. DOLLARS SINCE FILE TOTAL
FULL ESTIMATED COST ENTRY SESSION
130.00 187.55

FILE 'USPATFULL' ENTERED AT 13:08:22 ON 04 APR 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 13:08:22 ON 04 APR 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> s 103628-46-2/in
L14 286 103628-46-2/RN

=> d ibib 286

L14 ANSWER 286 OF 286 USPAT2 on STN
ACCESSION NUMBER: 2001:194589 USPAT2 Full-text
TITLE: Methods and apparatus for using controlled heat to regulate transdermal and controlled release delivery of fentanyl, other analgesics, and other medical substances

INVENTOR(S): Zhang, Jie, Salt Lake City, UT, UNITED STATES
Hull, Wade, Taylorsville, UT, UNITED STATES
Rigby, Larry, Salt Lake City, UT, UNITED STATES
Stanley, Theodore, Salt Lake City, UT, UNITED STATES
Zars, Inc., Salt Lake City, UT, UNITED STATES (U.S. corporation)

PATENT ASSIGNEE(S):

NUMBER KIND DATE

PATENT INFORMATION: US 6955819 B2 20051018
APPLICATION INFO.: US 2001-796250 20010228 (9)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-545591, filed on 7 Apr 2000, PENDING Division of Ser. No. US 1998-162890, filed on 29 Sep 1998, Pat. No. US 6245347

NUMBER DATE

PRIORITY INFORMATION: US 2000-185913P 20000229 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Dodson, Shelley A.
ASSISTANT EXAMINER: George, Konata M.

PATENT ASSIGNEE(S) : Merck & Co, Inc., Rahway, NJ, UNITED STATES (U.S. corporation)

PATENT INFORMATION: US 7196079 B2 20070327
WO 2005008007 20050106
APPLICATION INFO.: US 2004-562298 20040624 (10)
WO 2004-US20206 20040624
20051222 PCT 371 date

PRIORITY INFORMATION: US 2003-482674P 20030626 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Kifle, Bruck
LEGAL REPRESENTATIVE: Rose, David L., Rubin, David
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
LINE COUNT: 1945

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to compounds of Formula I:

##STR1## (where variables R.sup.1, R.sup.2, R.sup.3, R.sup.6, R.sup.7, G, J, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d ibib abs 58

L17 ANSWER 58 OF 60 USPATFULL on STN
ACCESSION NUMBER: 91:62807 USPATFULL Full-text
TITLE: Indole derivative
INVENTOR(S): Oxford, Alexander W., Royston, England
PATENT ASSIGNEE(S): Glaxo Group Limited, England (non-U.S. corporation)

PATENT INFORMATION: US 5037845 19910806
APPLICATION INFO.: US 1989-317682 19890301 (7)
RELATED APPLN. INFO.: Continuation of Ser. No. US 1987-82666, filed on 7 Aug 1987, now abandoned which is a continuation of Ser. No. US 1985-761392, filed on 1 Aug 1985, now abandoned

PRIORITY INFORMATION: GB 1984-19575 19840801
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Ceperley, Mary E.
LEGAL REPRESENTATIVE: Bacon & Thomas
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1, 5
LINE COUNT: 1276

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A compound of formula (I) ##STR1## and its physiologically acceptable salts and solvates are described as useful in treating and/or preventing pain resulting from dilatation of the cranial vasculature in particular migraine.

The compound (I) may be prepared, for example, by cyclizing a compound of formula (II) ##STR2##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d ibib abs 57

L17 ANSWER 57 OF 60 USPATFULL on STN
ACCESSION NUMBER: 1998:45217 USPATFULL Full-text
TITLE: Serotonin agonist in combination with a tachykinin receptor antagonist in the treatment or prevention of migraine
INVENTOR(S): Cohen, Marlene L., Carmel, IN, United States
Johnson, Kirk W., Indianapolis, IN, United States
Phebus, Lee A., Fountaintown, IN, United States
PATENT ASSIGNEE(S): Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)

PATENT INFORMATION: US 5744482 19980428
APPLICATION INFO.: US 1994-318391 19941005 (8)
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Spivack, Phyllis G.
LEGAL REPRESENTATIVE: Gaylo, Paul J., Boone, David E.
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1
LINE COUNT: 1252

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods for the treatment or prevention of migraines comprising administering to a mammal in need thereof a combination of a tachykinin receptor antagonist and a serotonin agonist are disclosed. The administration may be concurrent or sequential, with either of the two activities being administered first.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d ibib abs 56

L17 ANSWER 56 OF 60 USPATFULL on STN
ACCESSION NUMBER: 1999:1249 USPATFULL Full-text
TITLE: Method of treatment of migraine
INVENTOR(S): Peyman, Gholam A., 202 Gravier, Suite B, New Orleans, LA, United States 70112-2234

PATENT INFORMATION: US 5855907 19990105
APPLICATION INFO.: US 1997-828144 19970324 (8)
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Azpuru, Carlos A.
LEGAL REPRESENTATIVE: Dechert Price & Rhoads
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 450

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to, among other things, methods of treatment of migraine headache in humans with reduced side effects by the topical administration of a migraine -ameliorating effective amount of an opioid, singly, or in combination with other

pharmacological agents, including vasoconstrictors, antiinflammatory agents, antimicrobial agents, decongestants and non-opioid migraine drugs.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s 117 and crystalline
L18 11 L17 AND CRYSTALLINE

=> d 11b abs tot

L18 ANSWER 1 OF 11 USPATFULL on STN
ACCESSION NUMBER: 2007:64617 USPATFULL Full-text
TITLE: Preemptive prophylaxis of migraine
INVENTOR(S): Cady, Roger K., 631 Riverview Rd., Ozark, MO, UNITED STATES 65721
Guterman, Donna Lee, c/o Glaxo Wellcome Inc. Five Moore Dr., P.O. Box 13398, Research Triangle Park, NC, UNITED STATES 27709-3398
O'Quinn, Stephen Venson, c/o Glaxo Wellcome Inc. Five Moore Dr., P.O. Box 13398, Research Triangle Park, NC, UNITED STATES 27709-3398

PATENT INFORMATION:
APPLICATION INFO.: US 2000-575277 B1 20070313
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 1999-US9414, filed on 29 Apr 1999, PENDING Continuation-in-part of Ser. No. US 1998-185310, filed on 3 Nov 1998, Pat. No. US 6086092

NUMBER KIND DATE

US 7189753 B1 20070313
US 2000-575277 B1 20000522 (9)
Continuation-in-part of Ser. No. WO 1999-US9414, filed on 29 Apr 1999, PENDING Continuation-in-part of Ser. No. US 1998-185310, filed on 3 Nov 1998, Pat. No. US 6086092

NUMBER KIND DATE

US 1997-64879P 19971106 (60)
UTILITY
DOCUMENT TYPE: GRANTED
FILE SEGMENT: Kim, Vickie
PRIMARY EXAMINER: Husch & Eppenberger LLC, Rusche, H. Frederick
LEGAL REPRESENTATIVE: 9
NUMBER OF CLAIMS: 1
EXEMPLARY CLAIM:
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 753

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of preventing the headache phase of migraine in a human comprises administration of a 5HT.sub.1 receptor agonist or administration of an over-the-counter or nonprescription drug to said human exhibiting prodrome symptoms of migraine. Suitably, the method comprises administration of a migraine headache phase-preventing effective amount of the 5HT.sub.1 agonist or over-the-counter or nonprescription drug. There is disclosed a preemptive prophylaxis migraine method using the following cognitive tests: Simple Reaction Time; Running Memory Continuous Performance Task; Matching to Sample; Mathematical Processing Task; and interpreting the results as a percent of baseline indicator of need for prophylaxis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 2 OF 11 USPATFULL on STN
ACCESSION NUMBER: 2006:302361 USPATFULL Full-text
TITLE: Substituted indole compounds having NOS inhibitory activity

INVENTOR(S): Maddaford, Shawn, Mississauga, CANADA
Ramnauth, Jallal, Brampton, CANADA
Rakhit, Suman, Mississauga, CANADA
Patman, Joanne, Mississauga, CANADA
Renton, Paul, Toronto, CANADA

Annedi, Subhash C., Mississauga, CANADA

NUMBER KIND DATE

US 2006258721 A1 20061116
US 2006-404267 A1 20060413 (11)
PATENT INFORMATION:
APPLICATION INFO.:
PRIORITY INFORMATION: US 2005-670856P 20050413 (60).
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US
NUMBER OF CLAIMS: 74
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Page(s)
LINE COUNT: 6673
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention features inhibitors of nitric oxide synthase (NOS), particularly those that selectively inhibit neuronal nitric oxide synthase (nNOS) in preference to other NOS isoforms. The NOS inhibitors of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing conditions such as, for example, stroke, reperfusion injury, neurodegeneration, head trauma, CABG, migraine headache with and without aura, migraine with allodynia, central post-stroke pain (CSP), neuropathic pain, morphine/opioid induced tolerance and hyperalgesia.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 3 OF 11 USPATFULL on STN
ACCESSION NUMBER: 2006:273924 USPATFULL Full-text
TITLE: Delivery of compounds for the treatment of headache through an inhalation route

INVENTOR(S): Hale, Ron L., Woodside, CA, UNITED STATES
Rabinowitz, Joshua D., Princeton, NJ, UNITED STATES
Solias, Dennis W., San Francisco, CA, UNITED STATES
Zaffaroni, Alejandro C., Atherton, CA, UNITED STATES
Alexza Pharmaceuticals, Inc., Palo Alto, CA, UNITED STATES (U.S. corporation)

NUMBER KIND DATE

US 2006233717 A1 20061019
US 2006-385992 A1 20060321 (11)
Continuation-in-part of Ser. No. US 2004-792012, filed on 3 Mar 2004, GRANTED, Pat. No. US 7018621
Continuation of Ser. No. US 2002-155621, filed on 22 May 2002, GRANTED, Pat. No. US 6759029
Continuation-in-part of Ser. No. US 2004-766574, filed on 27 Jan 2004, GRANTED, Pat. No. US 7045118
Continuation of Ser. No. US 2003-735496, filed on 12 Dec 2003, GRANTED, Pat. No. US 7005121 Continuation of Ser. No. US 2002-154594, filed on 23 May 2002, GRANTED, Pat. No. US 6740309 Continuation-in-part of Ser. No. US 2004-792239, filed on 3 Mar 2004, GRANTED, Pat. No. US 7014840 Continuation of Ser. No. US 2002-155705, filed on 22 May 2002, GRANTED, Pat. No. US 6805854

NUMBER KIND DATE

US 2001-294203P 20010524 (60)
US 2001-317479P 20010905 (60)
US 2001-332280P 20011121 (60)
US 2001-336218P 20011030 (60)
US 2001-294203P 20010524 (60)
US 2001-317479P 20010905 (60)
PRIORITY INFORMATION:

FILE SEGMENT: 20010524 (60)
LEGAL REPRESENTATIVE: MERCK AND CO., INC, P O BOX 2000, RAHWAY, NJ.
APPLICATION 07065-0907, US
UTILITY 57
NUMBER OF CLAIMS: 1
EXEMPLARY CLAIM: 2148
LINE COUNT: 1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to compounds of Formula I: I (where variables R
#custom-character-00001## 17, R #custom-character-00002## / 2?, R #custom-character-
00003## 37, R #custom-character-00004## 4?, R #custom-character-00005## 6?, R
#custom-character-00006## 7?, G, J, U, V, W, X and Y are as defined herein) useful
as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in
which the CGRP is involved, such as headache, migraine and cluster headache. The
invention is also directed to pharmaceutical compositions comprising these compounds and
the use of these compounds and compositions in the prevention or treatment of such
diseases in which CGRP is involved. ##STRI##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 6 OF 11 USPATFULL on STN
ACCESSION NUMBER: 2006:125492 USPATFULL Full-text
TITLE: 3'-2-(Dimethylamino) ethyl-1-n-methyl-1h-indole-5-
methanesulfonamide and the succinate thereof
INVENTOR(S): Reddy, Manne Satyanarayana, Hyderabad, INDIA
Rajan, Srinivasan Thirumalai, Hyderabad, IN, UNITED STATES
Murthy, Mokkarala Suryanarayana, Hyderabad, IN, UNITED STATES
Prasad, Achampeta Kodanda Ram, Hyderabad, IN, UNITED STATES
PATENT ASSIGNER(S): Dr Reddy's Laboratories Limited, Hyderabad 500 016,
Andhra Pradesh, INDIA (non-U.S. corporation)

| NUMBER | KIND | DATE |
|-----------------|------|-----------------------|
| US 2006106227 | A1 | 20060518 |
| US 2004-516897 | A1 | 20040616 (10) |
| WO 2004-US19004 | | 20040616 |
| | | 20050705 PCT 371 date |

PATENT INFORMATION: IN 2002-45102 20020613
APPLICATION INFO.: IN 2002-45202 20020613
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: DR. REDDY'S LABORATORIES, INC., 200 SOMERSET CORPORATE
BLVD, SEVENTH FLOOR,, BRIDGEWATER, NJ, 08807-2862, US
NUMBER OF CLAIMS: 47
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Page(s)
LINE COUNT: 672
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A process for the preparation of highly pure Sumatriptan id described. A process for the
preparation of novel crystalline Form I and crystalline Form II of Sumatriptan succinate
is described. Sumatriptan is used for alleviating the pain of migraine headaches.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 7 OF 11 USPATFULL on STN
ACCESSION NUMBER: 2004:261840 USPATFULL Full-text
TITLE: Nr2b receptor antagonists for the treatment or
prevention of migraines
INVENTOR(S): Allen, Christopher, Doylestown, PA, UNITED STATES
Koblan, Ken S., Carversville, PA, UNITED STATES

US 2001-294203P 20010524 (60)
US 2001-317479P 20010905 (60)
UTILITY
APPLICATION
SWANSON & BRATSCHUN L.L.C., 1745 SHEA CENTER DRIVE,
SUITE 330, HIGHLANDS RANCH, CO, 80129, US
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
LINE COUNT: 1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to the delivery of migraine headache drugs through an
inhalation route. Specifically, it relates to aerosols containing migraine headache drugs
that are used in inhalation therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 4 OF 11 USPATFULL on STN
ACCESSION NUMBER: 2006:175340 USPATFULL Full-text
TITLE: Benzodiazepine cgrp receptor antagonists
INVENTOR(S): Burgey, Christopher S., Philadelphia, PA, UNITED STATES
Stump, Craig A., Pottstown, PA, UNITED STATES
Williams, Theresa M., Harleysville, NJ, UNITED STATES
NUMBER KIND DATE
US 2006148790 A1 20060706
US 7196079 B2 20070327
US 2004-562298 A1 20040624 (10)
WO 2004-US20206 20040624
20051222 PCT 371 date

| NUMBER | KIND | DATE |
|---|------|----------|
| US 2003-60482674 | | 20030626 |
| UTILITY | | |
| APPLICATION | | |
| LEGAL REPRESENTATIVE: MERCK AND CO., INC, P O BOX 2000, RAHWAY, NJ, | | |
| 07065-0907, US | | |
| 61 | | |
| EXEMPLARY CLAIM: 1 | | |
| LINE COUNT: 2196 | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to compounds of Formula I: ##STRI## (where variables
R.sup.1, R.sup.2, R.sup.3, R.sup.6, R.sup.7, G, J, W, X and Y are as defined herein)
useful as antagonists of CGRP receptors and useful in the treatment or prevention of
diseases in which the CGRP is involved, such as headache, migraine and cluster headache.
The invention is also directed to pharmaceutical compositions comprising these compounds
and the use of these compounds and compositions in the prevention or treatment of such
diseases in which CGRP is involved.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 5 OF 11 USPATFULL on STN
ACCESSION NUMBER: 2006:159976 USPATFULL Full-text
TITLE: Benzodiazepine cgrp receptor antagonists
INVENTOR(S): Burgey, Christopher S., UNITED STATES
NUMBER KIND DATE
US 2006135511 A1 20060622
US 2004-562297 A1 20040624 (10)
WO 2004-US20209 20040624
20051222 PCT 371 date
UTILITY

Sleeth, Timothy, Blue Bell, PA, UNITED STATES

INVENTOR(S):
NUMBER KIND DATE
US 2004204341 A1 20041014
US 2003-479923 A1 20031205 (10)
WO 2002-US21069 20020607

PATENT INFORMATION:
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MERCK AND CO INC, P O BOX 2000, RAHWAY, NJ, 070650907
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
LINE COUNT: 5753

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention encompasses a method for treating or preventing migraines in a mammalian patient in need of such treatment or prevention comprising administering to said patient an NR2B receptor antagonist in an amount that is effective to treat or prevent migraines. The invention also encompasses the combination of an NR2B antagonist with a cyclooxygenase-2 selective inhibitor, a calcitonin gene-related peptide receptor (CGRP) ligand, a leukotriene receptor antagonist or a 5HT-sub.1B/1D agonist for the treatment or prevention of migraines.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 8 OF 11 USPATFULL on STN
ACCESSION NUMBER: 2004-203899 USPATFULL Full-text
TITLE: Rapid absorption selective 5-HT agonist formulations
INVENTOR(S): Mezaache, Naima, McLean, VA, UNITED STATES
Mezaache, Djelila, Laurel, MD, UNITED STATES
Frisbee, Steve, Reston, VA, UNITED STATES
Maes, Paul, Toronto, CANADA

PATENT INFORMATION:
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: CROWELL & MORING LLP, INTELLECTUAL PROPERTY GROUP, P.O. BOX 14300, WASHINGTON, DC, 20044-4300
NUMBER OF CLAIMS: 135
EXEMPLARY CLAIM: 1
LINE COUNT: 2725

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides for a rapid absorption pharmaceutical composition comprising an effective amount of at least one selective 5-HT agonist, at least one spherization aid and at least one solubility enhancer. The composition of the invention is incorporated into microparticles, which may be subsequently taste-masked and incorporated into a variety of dosage forms for administration to a patient suffering from migraine

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 9 OF 11 USPATFULL on STN
ACCESSION NUMBER: 1998-45217 USPATFULL Full-text
TITLE: Serotonin agonist in combination with a tachykinin receptor antagonist in the treatment or prevention of

migraine

INVENTOR(S): Cohen, Marlene L., Carmel, IN, United States
Johnson, Kirk W., Indianapolis, IN, United States
Phebus, Lee A., Fountaintown, IN, United States
PATENT ASSIGNEE(S): Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)

NUMBER KIND DATE
US 5744482 19980428
US 1994-318391 19941005 (8)
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Spivack, Phyllis G.
LEGAL REPRESENTATIVE: Gaylo, Paul J., Boone, David E.
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
LINE COUNT: 1252

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods for the treatment or prevention of migraines comprising administering to a mammal in need thereof a combination of a tachykinin receptor antagonist and a serotonin agonist are disclosed. The administration may be concurrent or sequential, with either of the two activities being administered first.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 10 OF 11 USPATFULL on STN
ACCESSION NUMBER: 91-62807 USPATFULL Full-text
TITLE: Indole derivative
INVENTOR(S): Oxford, Alexander W., Royston, England
PATENT ASSIGNEE(S): Glaxo Group Limited, England (non-U.S. corporation)

NUMBER KIND DATE
US 5037845 19910806
US 1989-317682 19890301 (7)
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Ceperley, Mary E.
LEGAL REPRESENTATIVE: Bacon & Thomas
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1, 5
LINE COUNT: 1276

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A compound of formula (I) #STR1# and its physiologically acceptable salts and solvates are described as useful in treating and/or preventing pain resulting from dilatation of the cranial vasculature in particular migraine.

PATENT INFORMATION:
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Ceperley, Mary E.
LEGAL REPRESENTATIVE: Bacon & Thomas
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1, 5
LINE COUNT: 1276

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A compound of formula (I) #STR1# and its physiologically acceptable salts and solvates are described as useful in treating and/or preventing pain resulting from dilatation of the cranial vasculature in particular migraine.

The compound (I) may be prepared, for example, by cyclizing a compound of formula (II) #STR2#

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 11 OF 11 USPAT2 on STN
ACCESSION NUMBER: 2006:175340 USPAT2 Full-text
TITLE: Benzodiazepine CGRP receptor antagonists

INVENTOR(S): Burgey, Christopher S., Philadelphia, PA, UNITED STATES
Stump, Craig A., Pottstown, PA, UNITED STATES
Williams, Theresa M., Harleysville, NJ, UNITED STATES
PATENT ASSIGNEE(S): Merck & Co, Inc., Rahway, NJ, UNITED STATES (U.S. corporation)

PATENT INFORMATION: NUMBER KIND DATE
US 7196079 B2 20070327
WO 2005000807 20050106
APPLICATION INFO.: US 2004-562298 20040624 (10)
WO 2004-US20206 20040624
20051222 PCT 371 date

PRIORITY INFORMATION: NUMBER DATE
US 2003-482674P 20030626 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Kifle, Bruck
LEGAL REPRESENTATIVE: Rose, David L., Rubin, David
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
LINE COUNT: 1945
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to compounds of Formula I:

##STR1## (where variables R.sup.1, R.sup.2, R.sup.3, R.sup.6, R.sup.7, G, J, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> log hold
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY 88.86 SESSION 276.41
FULL ESTIMATED COST

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 13:30:56 ON 04 APR 2007

CN Imigrane
CN Imiject
CN Imitrex
CN Megrelan
CN Migragesin
CN Sumatriptan succinate
CN Sumitrex
MF C14 H21 N3 O2 S . C4 H6 O4
CI COM
SR CA
LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BEILSTEIN*, BIOSIS,
BIOTECHNO, CA, CAPLUS, CASREACT, CERN, CHEMCATS, CHEMLIST, CIN, CSHEM,
EMBASE, IMSCSEARCH, IMPSPATENTS, INSERSEARCH, IPA, MRCK*, PHAR, PIRA,
PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2,
USPATFULL
(*File contains numerically searchable property data)

CM 1
CRN 103628-46-2
CMF C14 H21 N3 O2 S



CM 2
CRN 110-15-6
CMF C4 H6 O4

HO2C-CH2-CH2-CO2H

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

157 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
160 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file uspatall
COST IN U.S. DOLLARS
FULL ESTIMATED COST
SINCE FILE ENTRY
TOTAL SESSION
57.55

FILE 'USPATFULL' ENTERED AT 10:45:58 ON 04 APR 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
FILE 'USPAT2' ENTERED AT 10:45:58 ON 04 APR 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l10
L11 106 L10

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTARHH1626

PASSWORD:
***** RECONNECTED TO STN INTERNATIONAL *****
SESSION RESUMED IN FILE 'REGISTRY' AT 10:45:17 ON 04 APR 2007
FILE 'REGISTRY' ENTERED AT 10:45:17 ON 04 APR 2007
COPYRIGHT (C) 2007 American Chemical Society (ACS)

COST IN U.S. DOLLARS
FULL ESTIMATED COST
SINCE FILE ENTRY
TOTAL SESSION
50.20

=> file reg
COST IN U.S. DOLLARS
FULL ESTIMATED COST
SINCE FILE ENTRY
TOTAL SESSION
50.20

FILE 'REGISTRY' ENTERED AT 10:45:22 ON 04 APR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 3 APR 2007 HIGHEST RN 929074-02-2
DICTIONARY FILE UPDATES: 3 APR 2007 HIGHEST RN 929074-02-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> s sumatriptan succinate/cn
L10 1 SUMATRIPTAN SUCCINATE/CN

=> d l10

L10 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN
RN 103628-48-4 REGISTRY
ED Entered STN: 09 Aug 1986
CN Butanedioic acid, compd. with 3-[2-(dimethylamino)ethyl]-N-methyl-1H-
indole-5-methanesulfonamide (1:1) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1H-Indole-5-methanesulfonamide, 3-[2-(dimethylamino)ethyl]-N-methyl-,
butanedioate (1:1) (9CI)

OTHER NAMES:
CN GR 43175C
CN Imigran

L11 ANSWER 106 OF 106
ACCESSION NUMBER: 2002:12064 USPAT2 Full-text
TITLE: Rapid-melt semi-solid compositions, methods of making same and methods of using same
INVENTOR(S): Cherukuri, Subraman Rao, Vienna, VA, United States
PATENT ASSIGNEE(S): Capricorn Pharma, Inc., Frederick, MD, United States (U.S. corporation)

| NUMBER | KIND | DATE |
|---|------|--------------|
| PATENT INFORMATION: | | |
| US 6589556 | B2 | 20030708 |
| US 2001-858885 | | 20010517 (9) |
| CONTINUATION-IN-PART OF SER. NO. US 2000-610489, FILED | | |
| ON 5 JUL 2000, NOW PATENTED, PAT. NO. US 6375982 | | |
| UTILITY | | |
| GRANTED | | |
| SPEAR, JAMES M. | | |
| FUBARA, BLESSING | | |
| NATH & ASSOCIATES PLLC, NATH, GARY M., MEYER, JERALD L. | | |
| 38 | | |
| EXEMPLARY CLAIM: | | |
| 1 | | |
| 0 DRAWING FIGURE(S); 0 DRAWING PAGE(S) | | |
| 1546 | | |
| LINE COUNT: | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

CAB A novel rapid-melt, semi-solid molded composition, including methods of making the same, and methods of using the same for the delivery of prophylactic and therapeutic active materials to a mammal wherein the prophylactic or therapeutic active is a psychotropic, a gastrointestinal therapeutic or a migraine therapeutic.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d ibib abs 105

LL1 ANSWER 105 OF 106
 USPAT2 ON STN
 2002:78243 USPAT2 Full-text
 Porous pacitaxel matrices and methods of manufacture
 thereof
 INVENTOR(s) :
 Straub, Julie, Winchester, MA, United States
 Bernstein, Howard, Cambridge, MA, United States
 Chickering, III, Donald E., Framingham, MA, United
 States
 Khattak, Sarwat, Amherst, MA, United States
 Randall, Greg, Somerville, MA, United States
 Acusphere, Inc., Cambridge, MA, United States (U.S.
 corporation)

| | NUMBER | KIND | DATE |
|-----------------------|--|------|--------------|
| PATENT INFORMATION: | US 6610317 | B2 | 20030826 |
| APPLICATION INFO.: | US 2001-798824 | | 20010302 (9) |
| RELATED APPLN. INFO.: | Continuation of Ser. No. WO 2000-US14578, filed on 25 May 2000 | | |

| | NUMBER | DATE |
|-----------------------|----------------------|---------------|
| PRIORITY INFORMATION: | | |
| | US 2000-186310P | 20000302 (60) |
| | US 1999-158659P | 19991008 (60) |
| | US 1999-136323P | 19990527 (60) |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | GRANTED | |
| PRIMARY EXAMINER: | Dees, Jose' G. | |
| ASSISTANT EXAMINER: | Dewitty, Robert M | |
| LEGAL REPRESENTATIVE: | Holland & Knight LLP | |

32 NUMBER OF CLAIMS:
1 EXEMPLARY CLAIM:
2 Drawing Figure(s); 1 Drawing Page(s)
775 LINE COUNT:
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Paclitaxel is provided in a porous matrix form, which allows the drug to be formulated without Cremophor and administered as a bolus. The paclitaxel matrices preferably are made using a process that includes (i) dissolving paclitaxel in a volatile solvent to form a paclitaxel solution, (ii) combining at least one pore forming agent with the paclitaxel solution to form an emulsion, suspension, or second solution, and (iii) removing the volatile solvent and pore forming agent from the emulsion, suspension, or second solution to yield the porous matrix of paclitaxel. The pore forming agent can be either a volatile liquid that is immiscible with the paclitaxel solvent or a volatile solid compound, preferably a volatile salt. In a preferred embodiment, spray drying is used to remove the solvents and the pore forming agent. In a preferred embodiment, microparticles of the porous paclitaxel matrix are reconstituted with an aqueous medium and administered parenterally, or processed using standard techniques into tablets or capsules for oral administration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s l11 and sumatriptan/clm
l112 51 L11 AND SUMATRIPTAN/CLM

=> d ibib abs 51

LL12 ANSWER 51 OF 51
 USPAT2 ON STN 2002:12064 USPAT2 Full-text
 Rapid-melt semi-solid compositions, methods of making
 same and methods of using same
 INVENTOR(S): Cherukuri, Subraman Rao, Vienna, VA, United States
 PATENT ASSIGNER(S): Capricorn Pharma, Inc., Frederick, MD, United States
 (U.S. corporation)

| | NUMBER | KIND | DATE |
|-----------------------|---|------|--------------|
| PATENT INFORMATION: | US 6589556 | B2 | 20030708 |
| APPLICATION INFO.: | US 2001-85885 | | |
| RELATED APPLN. INFO.: | Continuation-in-part of Ser. No. US 2000-610499, filed on 5 Jul 2000, now patented, Pat. No. US 6375982 | | 20010517 (9) |

UTILITY: UTILITY
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Speart, James M.
ASSISTANT EXAMINER: Fudara, Blessing
LEGAL REPRESENTATIVE: Nath & Associates PLLC, Nath, Gary M., Meyer, Jerald L.
NUMBER OF CLAIMS: 38
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0
DRAWING FIGURE(S): 0
DRAWING PAGE(S): 0
LINE COUNT: 1546

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A novel rapid-melt, semi-solid molded composition, including methods of making the same, and methods of using the same for the delivery of prophylactic and therapeutic active materials to a mammal wherein the prophylactic or therapeutic active is a psychotropic, gastrointestinal therapeutic or a migraine therapeutic.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d ibib abs 50

L12 ANSWER 50 OF 51 USPAT2 on STN
 ACCESSION NUMBER: 2004:158099 USPAT2 Full-text
 TITLE: Buccal, polar and non-polar spray or capsule containing
 drugs for treating disorders of the central nervous

AB Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring agent; formulation II: aqueous polar solvent, active compound, optionally optional flavoring agent, and propellant; formulation III: non-polar solvent, active compound, and optional flavoring agent; and formulation IV: non-polar solvent, active compound, and optional flavoring agent, and propellant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s 112 and sumatriptan/ab
L13 10 L12 AND SUMATRIPTAN/AB

=> d ibib abs tot

L13 ANSWER 1 OF 10 USP2FULL on STN
ACCESSION NUMBER: 2006:274081 USP2FULL Full-text
TITLE: Taste masked sumatriptan tablets and processes for their preparation

INVENTOR(S):
Kumar, T. Vijaya, Andhra Pradesh, INDIA
Roy, Sunilendu Bhushan, Maharashtra, INDIA
Malik, Rajiv, Wein, AUSTRIA

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|-----------------------|
| PATENT INFORMATION: | US 2006233875 | A1 | 20061019 |
| APPLICATION INFO.: | US 2003-521402 | A1 | 20030717 (10) |
| | WO 2003-1B2838 | | 20030717 |
| | | | 20060301 PCT 371 date |

PRIORITY INFORMATION: IN 2002-7592002 20020719
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: RANBAXY INC., 600 COLLEGE ROAD EAST, SUITE 2100, PRINCETON, NJ, 08540, US

NUMBER OF CLAIMS: 54
EXEMPLARY CLAIM: 1
LINE COUNT: 749

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The technical field of the present invention relates to uncoated, taste masked sumatriptan tablets for oral administration and processes for their preparation. It also relates to wax polished sumatriptan tablets and processes for their preparation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 2 OF 10 USP2FULL on STN
ACCESSION NUMBER: 2006:196517 USP2FULL Full-text
TITLE: Amorphous (sumatriptan) succinate

INVENTOR(S):
Reddy, Manne Satyanarayana, Hyderabad, INDIA
Rajan, Srinivasan Thirumalai, Hyderabad, INDIA
Murthy, Mokkara Surya Narayana, Hyderabad, INDIA
Prasad, Achampeta Kodanda Ram, Hyderabad, INDIA

| | NUMBER | KIND | DATE |
|-----------------------|----------------|------|---|
| PATENT INFORMATION: | US 2006167274 | A1 | 20060727 |
| APPLICATION INFO.: | US 2006-386608 | A1 | 20060322 (11) |
| RELATED APPLN. INFO.: | | | Continuation of Ser. No. US 2003-627399, filed on 25 Jul 2003, GRANTED, Pat. No. US 7034162 |

INVENTOR(S):
PATENT ASSIGNEE(S):
Dugger, III, Harry A., Flemington, NJ, UNITED STATES
Novadel Pharma, Inc., Flemington, NJ, UNITED STATES
(U.S. corporation)

NUMBER KIND DATE
US 6977070 B2 20051220
US 2003-726585 20031204 (10)
Division of Ser. No. US 2002-230060, filed on 29 Aug 2002, PENDING Continuation-in-part of Ser. No. US 2000-537118, filed on 29 Mar 2000, PENDING
Continuation-in-part of Ser. No. WO 1997-US17899, filed on 1 Oct 1997, PENDING
Utility
GRANTED

PRIMARY EXAMINER: Kunz, Gary
ASSISTANT EXAMINER: Haghighatian, Mina
LEGAL REPRESENTATIVE: Dickstein Shapiro Morin & Oshinsky LLP
NUMBER OF CLAIMS: 30
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 986

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring agent; formulation II: aqueous polar solvent, active compound, optionally optional flavoring agent, and propellant; formulation III: non-polar solvent, active compound, and optional flavoring agent; and formulation IV: non-polar solvent, active compound, and optional flavoring agent, and propellant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d ibib abs 49

L12 ANSWER 49 OF 51 USP22 Full-text
ACCESSION NUMBER: 2004:158100 USP22 Full-text
TITLE: Buccal, polar and non-polar spray or capsule containing drugs for treating pain
INVENTOR(S):
PATENT ASSIGNEE(S):
Dugger, III, Harry A., Flemington, NJ, UNITED STATES
Novadel Pharma, Inc., Flemington, NJ, UNITED STATES
(U.S. corporation)

NUMBER KIND DATE
US 6969508 B2 20051129
US 2003-726625 20031204 (10)
Division of Ser. No. US 2002-230059, filed on 29 Aug 2002, PENDING Continuation-in-part of Ser. No. US 2000-537118, filed on 29 Mar 2000, PENDING
Continuation-in-part of Ser. No. WO 1997-US17899, filed on 1 Oct 1997, PENDING
Utility
GRANTED

PRIMARY EXAMINER: Kunz, Gary
ASSISTANT EXAMINER: Haghighatian, Mina
LEGAL REPRESENTATIVE: Dickstein Shapiro Morin & Oshinsky LLP
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 821

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

INVENTOR(S): other antimigraine drugs for the treatment of migraine
RUDOLF, Klaus, Warthausen, GERMANY, FEDERAL REPUBLIC OF
DOODS, Henri, Warthausen, GERMANY, FEDERAL REPUBLIC OF
MUELLER, Stephan Georg, Warthausen, GERMANY, FEDERAL
REPUBLIC OF
ZAMPONI, Annette, Biberach, GERMANY, FEDERAL REPUBLIC
OF
LUSTENBERGER, Philipp, Warthausen, GERMANY. FEDERAL
REPUBLIC OF
ARNDT, Kirsten, Biberach, GERMANY, FEDERAL REPUBLIC OF
SCHAEZLE, Gerhard, Biberach-Mettenberg, GERMANY,
FEDERAL REPUBLIC OF
STENKAMP, Dirk, Biberach, GERMANY, FEDERAL REPUBLIC OF
Brickl, Rolf-Stefan, Warthausen, GERMANY, FEDERAL
REPUBLIC OF
Boehringer Ingelheim International GmbH, Ingelheim,
GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

PATENT ASSIGNEE(S):
Boehringer Ingelheim International GmbH, Ingelheim,
GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

PATENT INFORMATION:
APPLICATION INFO.:
US 2006142273 A1 20060629
US 2005-275169 A1 20051216 (11)

PRIORITY INFORMATION:
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MICHAEL P. MORRIS, BOEHRINGER INGELHEIM CORPORATION,
900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT,
06877-0368, US

NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
LINE COUNT: 1477

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a process for the treatment or prevention of indications which are selected from among the group comprising headaches, migraine and cluster headaches, this process comprising the joint administration of a therapeutically effective amount of a selected CGRP antagonist (A), a physiologically acceptable salt thereof or a hydrate of the salt and a therapeutically effective amount of a second or third active anti-migraine medicament (B), particularly sumatriptan, zolmitriptan or dihydroergotamine or a physiologically acceptable salt thereof, and to the corresponding pharmaceutical compositions and the preparation thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 5 OF 10 USPATFULL ON STN
ACCESSION NUMBER: 2006:125492 USPATFULL Full-text
TITLE: 3'-2-(Dimethylamino) ethyl 1-n-methyl-1h-indole-5-methanesulfonamide and the succinate thereof

INVENTOR(S): Reddy, Manne Satyanarayana, Hyderabad, INDIA
Rajan, Srinivasan Thirumalai, Hyderabad, IN, UNITED STATES
Murthy, Mokkarala Suryanarayana, Hyderabad, IN, UNITED STATES
Prasad, Achampeta Kodanda Ram, Hyderabad, IN, UNITED STATES
Dr Reddy's Laboratories Limited, Hyderabad 500 016, Andhra Pradesh, INDIA (non-U.S. corporation)

PATENT INFORMATION:
APPLICATION INFO.:
US 2006106227 A1 20060518
US 2004-516897 A1 20040616 (10)
WO 2004-US19004 20050705 PCT 371 date

INVENTOR(S):
RUDOLF, Klaus, Warthausen, GERMANY, FEDERAL REPUBLIC OF
DOODS, Henri, Warthausen, GERMANY, FEDERAL REPUBLIC OF
MUELLER, Stephan Georg, Warthausen, GERMANY, FEDERAL
REPUBLIC OF
ZAMPONI, Annette, Biberach, GERMANY, FEDERAL REPUBLIC
OF
LUSTENBERGER, Philipp, Warthausen, GERMANY. FEDERAL
REPUBLIC OF
ARNDT, Kirsten, Biberach, GERMANY, FEDERAL REPUBLIC OF
SCHAEZLE, Gerhard, Biberach-Mettenberg, GERMANY,
FEDERAL REPUBLIC OF
STENKAMP, Dirk, Biberach, GERMANY, FEDERAL REPUBLIC OF
Brickl, Rolf-Stefan, Warthausen, GERMANY, FEDERAL
REPUBLIC OF
Boehringer Ingelheim International GmbH, Ingelheim,
GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

PATENT ASSIGNEE(S):
Boehringer Ingelheim International GmbH, Ingelheim,
GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

PATENT INFORMATION:
APPLICATION INFO.:
US 2006142273 A1 20060629
US 2005-275169 A1 20051216 (11)

PRIORITY INFORMATION:
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MICHAEL P. MORRIS, BOEHRINGER INGELHEIM CORPORATION,
900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT,
06877-0368, US

NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
LINE COUNT: 1477

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a process for the treatment or prevention of indications which are selected from among the group comprising headaches, migraine and cluster headaches, this process comprising the joint administration of a therapeutically effective amount of a selected CGRP antagonist (A), a physiologically acceptable salt thereof or a hydrate of the salt and a therapeutically effective amount of a second or third active anti-migraine medicament (B), particularly sumatriptan, zolmitriptan or dihydroergotamine or a physiologically acceptable salt thereof, and to the corresponding pharmaceutical compositions and the preparation thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 5 OF 10 USPATFULL ON STN
ACCESSION NUMBER: 2006:125492 USPATFULL Full-text
TITLE: 3'-2-(Dimethylamino) ethyl 1-n-methyl-1h-indole-5-methanesulfonamide and the succinate thereof

INVENTOR(S): Reddy, Manne Satyanarayana, Hyderabad, INDIA
Rajan, Srinivasan Thirumalai, Hyderabad, IN, UNITED STATES
Murthy, Mokkarala Suryanarayana, Hyderabad, IN, UNITED STATES
Prasad, Achampeta Kodanda Ram, Hyderabad, IN, UNITED STATES
Dr Reddy's Laboratories Limited, Hyderabad 500 016, Andhra Pradesh, INDIA (non-U.S. corporation)

PATENT INFORMATION:
APPLICATION INFO.:
US 2006106227 A1 20060518
US 2004-516897 A1 20040616 (10)
WO 2004-US19004 20050705 PCT 371 date

PRIORITY INFORMATION: GB 2003-17904 20030731
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Daniel F. Coughlin, Esq., Mintz Levin Cohn Ferris
Glovsky and Popeo PC, Chrysler Center, 666 Third
Avenue, New York, NY, 10017
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: CLM-001-9
LINE COUNT: 618
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention is concerned with a unit dosage form containing sumatriptan and metoclopramide. The unit dosage form is so configured that a portion of the sumatriptan dose is provided in a first phase adapted for immediate release of sumatriptan, and a second portion is contained in a second phase adapted for the sustained release of sumatriptan.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 8 OF 10 USPATFULL on STN
ACCESSION NUMBER: 2004:185116 USPATFULL Full-text
TITLE: Amorphous form of 3-[2-(dimethylamino) ethyl]-N-methyl-1H-indole-5-methane sulfonamide succinate (sumatriptan succinate)
INVENTOR(S): Reddy, Manne Satyanarayana, Hyderabad, INDIA
Murthy, Srinivasan Thirumalai, Hyderabad, INDIA
Murthy, Mokkara Surya Narayana, Hyderabad, INDIA
Prasad, Achampeta Kodanda Ram, Hyderabad, INDIA
PATENT ASSIGNEE(S): DR. REDDY'S LABORATORIES LIMITED (non-U.S. corporation)
DR. REDDY'S LABORATORIES, INC. (non-U.S. corporation)

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|---------------|
| PATENT INFORMATION: | US 2004143002 | A1 | 20040722 |
| APPLICATION INFO.: | US 7034162 | B2 | 20060425 |
| | US 2003-627399 | A1 | 20030725 (10) |

PRIORITY INFORMATION: IN 2002-5942002 20020812
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: LADAS & PARRY, 26 WEST 61ST STREET, NEW YORK, NY, 10023
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 282
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to an amorphous form of Sumatriptan succinate of Formula (1). The present invention also relates to process for the preparation of an amorphous form of Sumatriptan succinate. The process for the preparation of an amorphous form of Sumatriptan succinate comprises refluxing an aqueous mixture of Sumatriptan or its succinate salt in alcoholic solvents such as methanol or nitrile solvents such as acetonitrile followed by evaporation of the solvent from the filtrate. The resulting residue is triturated with water immiscible aromatic or aliphatic hydrocarbon solvents such as cyclohexane to afford an amorphous form of Sumatriptan succinate.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 9 OF 10 USPATFULL on STN
ACCESSION NUMBER: 2004:177749 USPATFULL Full-text
TITLE: Buccal, polar and non-polar spray containing sumatriptan
INVENTOR(S): Dugger, Harry A., III, Flemington, NJ, UNITED STATES
Abd El-Shafy, Mohammed, Hauppauge, NY, UNITED STATES

PRIORITY INFORMATION: IN 2002-45102 20020613
IN 2002-45202 20020613
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: DR. REDDY'S LABORATORIES, INC., 200 SOMERSET CORPORATE
BLVD, SEVENTH FLOOR,, BRIDGEWATER, NJ, 08807-2862, US
47
NUMBER OF CLAIMS: 8 Drawing Page(s)
EXEMPLARY CLAIM: 1
LINE COUNT: 672
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A process for the preparation of highly pure Sumatriptan is described. A process for the preparation of novel crystalline Form I and crystalline Form II of Sumatriptan succinate is described. Sumatriptan is used for alleviating the pain of migraine headaches.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 6 OF 10 USPATFULL on STN
ACCESSION NUMBER: 2006:3533 USPATFULL Full-text
TITLE: Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
INVENTOR(S): Ahmed, Salah U., New City, NY, UNITED STATES
Li, Lianli, Pomona, NY, UNITED STATES
Naini, Venkatesh, Parsippany, NJ, UNITED STATES

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|---------------|
| PATENT INFORMATION: | US 2006002989 | A1 | 20060105 |
| APPLICATION INFO.: | US 2005-149444 | A1 | 20050610 (11) |

PRIORITY INFORMATION: US 2004-578286P 20040610 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STERNE, KESSLER, GOLDSTEIN & FOX PLLC, 1100 NEW YORK
AVENUE, N.W., WASHINGTON, DC, 20005, US
NUMBER OF CLAIMS: 37
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Page(s)
LINE COUNT: 973
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to pharmaceutical compositions comprising sumatriptan succinate and sodium caprate for increased absorption of sumatriptan succinate across biological membranes. The invention is also directed to methods of making the pharmaceutical compositions and uses thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 7 OF 10 USPATFULL on STN
ACCESSION NUMBER: 2005:38196 USPATFULL Full-text
TITLE: Pharmaceutical compositions comprising sumatriptan and metoclopramide, and methods of use thereof
INVENTOR(S): Vergnault, Guy, Loechle, FRANCE

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|---------------|
| PATENT INFORMATION: | US 2005032876 | A1 | 20050210 |
| APPLICATION INFO.: | US 2004-888324 | A1 | 20040709 (10) |

form of Sumatriptan succinate. The process for the preparation of an amorphous form of Sumatriptan succinate comprises refluxing an aqueous mixture of Sumatriptan or its succinate salt in alcoholic solvents such as methanol or nitrile solvents such as acetonitrile followed by evaporation of the solvent from the filtrate. The resulting residue is triturated with water immiscible aromatic or aliphatic hydrocarbon solvents such as cyclohexane to afford an amorphous form of Sumatriptan succinate.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>
=>
=> log hold
COST IN U.S. DOLLARS
FULL ESTIMATED COST
SINCE FILE ENTRY
TOTAL SESSION
130.00
187.55

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 11:26:25 ON 04 APR 2007

AB Buccal aerosol sprays or capsules using polar and non-polar solvents have now been developed which provide sumatriptan for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, sumatriptan, and optional flavoring agent; formulation II: aqueous polar solvent, sumatriptan, optionally flavoring agent, and propellant; formulation III: non-polar solvent, sumatriptan, and optional flavoring agent; formulation IV: non-polar solvent, sumatriptan, optional flavoring agent, and propellant; formulation V: a mixture of a polar solvent and a non-polar solvent, sumatriptan, and optional flavoring agent; formulation VI: a mixture of a polar solvent and a non-polar solvent, sumatriptan, optional flavoring agent, and propellant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 10 OF 10 USPAT2 on STN
ACCESSION NUMBER: 2004:185116 USPAT2 Full-text
TITLE: Amorphous form of 3-(2-(dimethylamino) ethyl)-N-methyl-LH-indole-5-methane sulfonamide succinate (sumatriptan succinate)
INVENTOR(S): Reddy, Manne Satyanarayana, Hyderabad, INDIA
Murthy, Srinivasan Thirumalai, Hyderabad, INDIA
Prasad, Achampeta Kodanda Ram, Hyderabad, INDIA
Dr. Reddy's Laboratories Limited, Hyderabad, INDIA (non-U.S. corporation)
PATENT ASSIGNEE(S): Dr. Reddy's Laboratories, Inc., Upper Saddle River, NJ, UNITED STATES (U.S. corporation)

| NUMBER | KIND | DATE |
|----------------|------|---------------|
| US 7034162 | B2 | 20060425 |
| US 2003-627399 | | 20030725 (10) |

| NUMBER | DATE |
|-----------------|----------|
| IN 2000-5942002 | 20000812 |

PATENT INFORMATION: IN 2000-5942002 20000812
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Soloia, Taofiq
ASSISTANT EXAMINER: Shiao, Robert
LEGAL REPRESENTATIVE: Franks, Robert A., Cepeda, Milagros A., Pergament, Edward D.

NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 266

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to an amorphous form of Sumatriptan succinate of Formula (1). The present invention also relates to process for the preparation of an amorphous